Maria Beumont Selected Research

Simeprevir

6/2020	Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study.
1/2019	JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1.
12/2017	Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
1/2017	Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.
5/2015	Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.
5/2015	Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.
11/2014	Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
8/2014	Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Beumont Research Topics

Disease

15	Infections 01/2023 - 06/2011
8	Chronic Hepatitis C 01/2019 - 02/2011
3	Chronic Hepatitis B 01/2023 - 11/2022
3	Fibrosis (Cirrhosis) 01/2019 - 10/2012
1	Hepatitis B 01/2023
1	Portal Hypertension 06/2020
1	Liver Diseases (Liver Disease) 06/2020
1	Persistent Infection 11/2014
1	Fatigue 08/2014
1	Insulin Resistance 10/2012
1	Hepatitis C 01/2012
1	Anemia 06/2011
1	Leukopenia 06/2011
1	Neutropenia 06/2011

Drug/Important Bio-Agent (IBA)

10	Ribavirin (Virazole)FDA LinkGeneric 01/2017 - 02/2011
8	SimeprevirIBA 06/2020 - 08/2014
8	telaprevirIBA 05/2014 - 02/2011
5	Antiviral Agents (Antivirals)IBA 01/2023 - 09/2011
5	Protease Inhibitors (Protease Inhibitor)IBA 12/2017 - 01/2013
3	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2023 - 11/2022
3	JNJ-56136379IBA 01/2023 - 11/2022
3	InterferonsIBA 01/2019 - 01/2013
3	peginterferon alfa-2a (Pegasys)FDA Link 09/2011 - 02/2011
2	Small Interfering RNA (siRNA)IBA 01/2023 - 11/2022
2	Hepatitis B e AntigensIBA 01/2023 - 01/2023
2	SofosbuvirIBA 06/2020 - 11/2014
1	Tenofovir (Viread)FDA Link 01/2023
1	Alanine Transaminase (SGPT)IBA 01/2023
1	AntigensIBA 01/2023
1	entecavir FDA Link 01/2023
1	DNA (Deoxyribonucleic Acid)IBA 01/2023
1	daclatasvirIBA 06/2020
1	odalasvirIBA 01/2019
1	sofosbuvir drug combination ledipasvirIBA 12/2017
1	ledipasvirIBA 12/2017
1	LDL CholesterolIBA 10/2012
1	RNA (Ribonucleic Acid)IBA 09/2011

Therapy/Procedure

7	Therapeutics 01/2023 - 06/2011
2	Aftercare (After-Treatment) 07/2013 - 10/2012
1	Duration of Therapy 06/2020
1	Retreatment 06/2011